Skip to main content

Viibryd Disease Interactions

There are 6 disease interactions with Viibryd (vilazodone).

Major

Antidepressants (applies to Viibryd) suicidality

Major Potential Hazard, Moderate plausibility. Applicable conditions: Depression, Bipolar Disorder

Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older. Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs. Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide. Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes. Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider. Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.

References

  1. "Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc. (2022):
  2. "Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals) (2022):
  3. "Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc (2019):
  4. "Product Information. Zyban (buPROPion)." GlaxoSmithKline (2021):
  5. "Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline (2020):
  6. "Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline (2020):
  7. "Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals) (2022):
  8. "Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc (2020):
  9. "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc (2021):
  10. "Product Information. Vraylar (cariprazine)." Allergan Inc (2019):
  11. "Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc (2019):
  12. "Product Information. SEROquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals (2022):
  13. "Product Information. Viibryd (vilazodone)." Allergan, Inc. USA (2021):
  14. "Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America (2021):
  15. "Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc. (2022):
View all 15 references
Moderate

Antidepressants (applies to Viibryd) angle closure glaucoma

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Glaucoma (Narrow Angle)

Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy. Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible. The use of these drugs in patients with untreated anatomically narrow angles should be avoided.

References

  1. "Product Information. Serzone (nefazodone)." Bristol-Myers Squibb (2001):
  2. "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC (2011):
  3. "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America (2013):
Moderate

Antidepressants (applies to Viibryd) bleeding

Moderate Potential Hazard, Moderate plausibility.

Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage. Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.

References

  1. "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC (2011):
  2. "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America (2013):
Moderate

Vilazodone (applies to Viibryd) hyponatremia

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Dehydration, SIADH

Treatment with vilazodone may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.

References

  1. "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC (2011):
Moderate

Vilazodone (applies to Viibryd) mixed/manic episode

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Depression, Bipolar Disorder, Mania

Therapy with vilazodone may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.

References

  1. "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC (2011):
Moderate

Vilazodone (applies to Viibryd) seizure disorder

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Seizures

Therapy with vilazodone should be administered cautiously in patients with epilepsy or a history of seizure disorder.

References

  1. "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC (2011):

Viibryd drug interactions

There are 404 drug interactions with Viibryd (vilazodone).

Viibryd alcohol/food interactions

There is 1 alcohol/food interaction with Viibryd (vilazodone).


Report options

Share by QR Code
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.